Illumina, Inc. (NASDAQ:ILMN) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 18.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,292 shares of the life sciences company’s stock after selling 290 shares during the period. SG Americas Securities LLC’s holdings in Illumina were worth $173,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Empowered Funds LLC lifted its stake in shares of Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after purchasing an additional 66 shares in the last quarter. Caprock Group LLC raised its holdings in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after acquiring an additional 83 shares in the last quarter. Integrated Advisors Network LLC lifted its position in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the last quarter. Moors & Cabot Inc. raised its position in shares of Illumina by 1.7% during the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after acquiring an additional 95 shares in the last quarter. Finally, Carson Advisory Inc. boosted its holdings in shares of Illumina by 3.8% in the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock valued at $360,000 after buying an additional 102 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Down 9.6 %

Shares of ILMN stock opened at $111.06 on Monday. The firm has a market cap of $17.61 billion, a PE ratio of -14.46 and a beta of 1.10. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The stock has a 50 day moving average of $136.70 and a 200-day moving average of $135.43. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, equities analysts predict that Illumina, Inc. will post 4.42 EPS for the current year.

Wall Street Analyst Weigh In

ILMN has been the subject of several analyst reports. Leerink Partners boosted their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their price objective on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price for the company in a report on Thursday, October 17th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and reduced their price target for the stock from $177.00 to $140.00 in a research report on Friday. Nine analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $161.40.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.